Literature DB >> 16871410

Cyclooxygenase-2 polymorphisms and risk of systemic lupus erythematosus in Koreans.

Min-Young Her1, Ahmed El-Sohemy, Marilyn C Cornelis, Tae-Hwan Kim, Sang-Cheol Bae.   

Abstract

Cyclooxygenase-2 (COX-2) is a key regulatory enzyme in the synthesis of prostanoids associated with trauma and inflammation. Upregulation of COX-2 in human lupus T cells resists anergy and apotosis. We investigated the COX-2 gene for functional variants that may influence susceptibility, clinical outcomes and severity of systemic lupus erythematosus (SLE) in a Korean population. The study included 345 patients with SLE and 400 unrelated healthy controls. Genotyping for the -765G --> C polymorphism of COX-2 was performed by PCR-RFLP analysis. No difference in the distribution of the genotype frequencies between patients and controls was found. COX-2 genotypes were not associated with clinical features except hematologic abnormalities and anti-RNP antibody. We did not detect any association between COX-2 genotype and disease severity in SLE patients. These results suggest that the -765G --> C polymorphism of COX-2 does not play a significant role in the development of SLE in a Korean population. A possible protective effect of the low activity C allele against the production of anti-RNP antibodies merits further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16871410     DOI: 10.1007/s00296-006-0162-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  17 in total

1.  Functional characterization of cyclooxygenase-2 polymorphisms.

Authors:  E Fritsche; S J Baek; L M King; D C Zeldin; T E Eling; D A Bell
Journal:  J Pharmacol Exp Ther       Date:  2001-11       Impact factor: 4.030

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis.

Authors:  C Zoja; A Benigni; M Noris; D Corna; F Casiraghi; M Pagnoncelli; D Rottoli; M Abbate; G Remuzzi
Journal:  Kidney Int       Date:  2001-08       Impact factor: 10.612

Review 4.  Cyclooxygenase in biology and disease.

Authors:  R N Dubois; S B Abramson; L Crofford; R A Gupta; L S Simon; L B Van De Putte; P E Lipsky
Journal:  FASEB J       Date:  1998-09       Impact factor: 5.191

5.  Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2.

Authors:  T Kosaka; A Miyata; H Ihara; S Hara; T Sugimoto; O Takeda; E Takahashi; T Tanabe
Journal:  Eur J Biochem       Date:  1994-05-01

6.  Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis.

Authors:  Y Refaeli; L Van Parijs; C A London; J Tschopp; A K Abbas
Journal:  Immunity       Date:  1998-05       Impact factor: 31.745

7.  A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke.

Authors:  Francesco Cipollone; Elena Toniato; Stefano Martinotti; Maria Fazia; Annalisa Iezzi; Chiara Cuccurullo; Barbara Pini; Sebastiano Ursi; Gianfranco Vitullo; Maurizio Averna; Marcello Arca; Anna Montali; Filomena Campagna; Sante Ucchino; Francesco Spigonardo; Stefano Taddei; Agostino Virdis; Giovanni Ciabattoni; Alberto Notarbartolo; Franco Cuccurullo; Andrea Mezzetti
Journal:  JAMA       Date:  2004-05-12       Impact factor: 56.272

8.  Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis.

Authors:  M Hamberg; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1973-03       Impact factor: 11.205

Review 9.  Activation-induced cell death in T cells.

Authors:  Douglas R Green; Nathalie Droin; Michael Pinkoski
Journal:  Immunol Rev       Date:  2003-06       Impact factor: 12.988

Review 10.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03
View more
  1 in total

1.  PharmGKB summary: very important pharmacogene information for PTGS2.

Authors:  Caroline F Thorn; Tilo Grosser; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-09       Impact factor: 2.089

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.